Costs and Cost-effectiveness of Subcutaneous DMPA through Different Delivery Channels: What the Evidence Tells Us

Date of Publication
2020

Recent evidence from African countries indicates that DMPA-SC may help reduce service delivery costs by catalyzing community-based distribution and remote provision of injectable contraception. Moreover, self-injection of DMPA-SC—when compared with clinic administration of traditional injectables—is not just cost-effective but cost saving when accounting for costs to both women and health systems.

New evidence shows that women who self-inject DMPA-SC continue using injectable contraception longer than those who receive injections from providers, which translates to fewer unintended pregnancies.